Shots:

• The collaboration between MD Anderson and Rigel Pharmaceuticals is focused on assessing olutasidenib's potential for treating newly diagnosed & r/r patients with AML, higher-risk MDS, and MPN.
• Under the collaboration Rigel will contribute $15M in milestone payments & study materials throughout the five-year collaboration, with the company maintaining exclusive rights to its programs within the partnership
• Rigel and MD Anderson will jointly lead clinical development efforts through a joint steering committee. Olutasidenib is already been approved by the US FDA for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation

Ref: MD Anderson Cancer Center  | Image: Rigel Pharmaceuticals

Related News:- Rigel Entered into an Exclusive WW License Agreement with Forma to Develop and Commercialize Olutasidenib for Acute Myeloid Leukemia

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com